Wednesday, December 17, 2025 | 01:11 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Glp1

GLP-1 weight-loss drugs likely to see value growth slowing down

Entry of generics post March 2026, patient dropouts to affect sales values, say experts

GLP-1 weight-loss drugs likely to see value growth slowing down
Updated On : 15 Dec 2025 | 12:13 AM IST

Ozempic in India: What it does and how it fits into a growing health crisis

From regulating appetite to improving blood sugar control, GLP-1 drugs like Ozempic are emerging as powerful metabolic tools at a time when India urgently needs better solutions

Ozempic in India: What it does and how it fits into a growing health crisis
Updated On : 12 Dec 2025 | 4:14 PM IST

Novo Nordisk launches Ozempic in India at ₹2,200/week amid patent battles

Ozempic debuts in India at ₹2,200 per week, offering a new treatment option for type 2 diabetes as demand grows for effective and easy-to-use metabolic health therapies

Novo Nordisk launches Ozempic in India at ₹2,200/week amid patent battles
Updated On : 12 Dec 2025 | 2:35 PM IST